HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry

被引:10
|
作者
Cordova, Claudio [1 ,2 ]
Munoz, Roberto [2 ,3 ]
Olivares, Rodrigo [3 ,4 ]
Minonzio, Jean-Gabriel [2 ,3 ,4 ,5 ]
Lozano, Carlo [6 ]
Gonzalez, Paulina [6 ,7 ]
Marchant, Ivanny [8 ]
Gonzalez-Arriagada, Wilfredo [9 ,10 ]
Olivero, Pablo [1 ,2 ]
机构
[1] Univ Valparaiso, Fac Med, Cell Funct & Struct Lab EFC Lab, 2664 Hontaneda, Valparaiso 2341386, Chile
[2] Univ Valparaiso, Fac Engn, PhD Program Hlth Sci & Engn, Valparaiso 2362735, Chile
[3] Univ Valparaiso, Fac Engn, Sch Informat Engn, Valparaiso 2362735, Chile
[4] Univ Valparaiso, Fac Engn, Ctr Res & Dev Hlth Engn, Valparaiso 2362735, Chile
[5] Univ Valparaiso, Fac Engn, Millennium Inst Intelligent Healthcare iHEALTH, Valparaiso 2362735, Chile
[6] Carlos Van Buren Hosp, Pathol Anat Serv, Valparaiso 2340105, Chile
[7] Andres Bello Natl Univ UNAB, Sch Med Technol, Vina Del Mar 2520000, Chile
[8] Univ Valparaiso, Fac Med, Med Modeling Lab, Valparaiso 2362735, Chile
[9] Univ Los Andes, Fac Dent, Santiago 7620086, Chile
[10] Univ Los Andes, Biomed Res & Innovat Ctr CIIB, Santiago 7620086, Chile
关键词
breast cancer; HER2; IHC; ML; SHAP; RECEPTOR; EXPRESSION; WOMEN; CONSENSUS;
D O I
10.3892/ol.2022.13630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immunohistochemical (IHC) evaluation of epidermal growth factor 2 (HER2) for the diagnosis of breast cancer is still qualitative with a high degree of inter-observer variability, and thus requires the incorporation of complementary techniques such as fluorescent in situ hybridization (FISH) to resolve the diagnosis. Implementing automatic algorithms to classify IHC biomarkers is crucial for typifying the tumor and deciding on therapy for each patient with better performance. The present study aims to demonstrate that, using an explainable Machine Learning (ML) model for the classification of HER2 photomicrographs, it is possible to determine criteria to improve the value of IHC analysis. We trained a logistic regression-based supervised ML model with 393 IHC microscopy images from 131 patients, to discriminate between upregulated and normal expression of the HER2 protein. Pathologists' diagnoses (IHC only) vs. the final diagnosis complemented with FISH (IHC + FISH) were used as training outputs. Basic performance metrics and receiver operating characteristic curve analysis were used together with an explainability algorithm based on Shapley Additive exPlanations (SHAP) values to understand training differences. The model could discriminate amplified IHC from normal expression with better performance when the training output was the IHC + FISH final diagnosis (IHC vs. IHC + FISH: area under the curve, 0.94 vs. 0.81). This may be explained by the increased analytical impact of the membrane distribution criteria over the global intensity of the signal, according to SHAP value interpretation. The classification model improved its performance when the training input was the final diagnosis, downplaying the weighting of the intensity of the IHC signal, suggesting that to improve pathological diagnosis before FISH consultation, it is necessary to emphasize subcellular patterns of staining.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [12] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    LABORATORY INVESTIGATION, 2019, 99
  • [13] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    MODERN PATHOLOGY, 2019, 32
  • [14] Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification
    Lee, Andrew H. S.
    Key, Heather P.
    Bell, Jane A.
    Hodi, Zsolt
    Ellis, Ian O.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (06) : 490 - 492
  • [15] A Comparative Analysis of the Value of Her2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of Her2 "LOW" Breast Cancers
    Bhardwaj, Swati
    Kandel, Avi
    Collins, Victoria
    Zeizafoun, Nebras
    Zeng, Jennifer
    Jaffer, Shabnam
    LABORATORY INVESTIGATION, 2023, 103 (03) : S103 - S103
  • [16] Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer
    Tseng, Yu-Fen
    Li, Yu-Chia
    Lee, Yi-Hsuan
    Hu, Hsiang-We
    Zhang, Man-San
    Hung, Tze-Chun
    Lien, Huang-Chun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (03) : e48 - e56
  • [17] HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma
    Perron, Marjorie
    Wen, Hannah Y.
    Hanna, Matthew G.
    Brogi, Edi
    Ross, Dara S.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (08) : 979 - 987
  • [18] Status evaluation of HER2 in breast cancerology by immunohistochemistry
    Bekkouche, Z.
    Kahia-Tani, S.
    BULLETIN DU CANCER, 2007, 94 (06) : 571 - 571
  • [19] Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
    Agersborg, Sally
    Mixon, Christopher
    Thanh Nguyen
    Aithal, Sramila
    Sudarsanam, Sucha
    Blocker, Forrest
    Weiss, Lawrence
    Gasparini, Robert
    Jiang, Shiping
    Chen, Wayne
    Hess, Gregory
    Albitar, Maher
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 321 - 328
  • [20] Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
    Agersborg, Sally
    Mixon, Christopher
    Thanh Nguyen
    Aithal, Sramila
    Blocker, Forrest
    Weiss, Lawrence
    Gasparini, Robert
    Jiang, Shiping
    Chen, Wayne
    Hess, Gregory
    Albitar, Maher
    CANCER RESEARCH, 2018, 78 (13)